Compare ELMD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | GNLX |
|---|---|---|
| Founded | 1992 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 113.6M |
| IPO Year | 2010 | 2022 |
| Metric | ELMD | GNLX |
|---|---|---|
| Price | $23.29 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $36.00 | $19.80 |
| AVG Volume (30 Days) | 43.2K | ★ 151.5K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | 9.47 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $54,716,000.00 | $8,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $42.23 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $1.99 |
| 52 Week High | $30.73 | $8.54 |
| Indicator | ELMD | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 48.69 |
| Support Level | $17.87 | $2.54 |
| Resistance Level | $25.31 | $3.00 |
| Average True Range (ATR) | 0.88 | 0.16 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 5.56 | 56.00 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.